Huveaux PLC
13 December 2007
For immediate release
Huveaux PLC
('Huveaux' or the 'Company')
Offer talks terminated
Huveaux announced on 22 October 2007 that it had received preliminary approaches
from a number of private equity houses and subsequently confirmed on 12 November
2007 that the Company was in detailed discussions with August Equity LLP
('August Equity') as regards a possible offer for the Company.
However, following detailed discussions, it has not been possible to reach
agreement on a proposal which fully values the Company. Therefore, offer related
discussions have now been terminated with all parties.
Trading across the Group has been satisfactory in the key final quarter of the
year. The Board confirms that it expects trading EBITDA for the current
financial year to be approximately £6.0 million.
In its Interim Results announced on 26 July 2007, the Board noted that it had
initiated an operational and profit improvement programme and highlighted cost
reduction initiatives across the Company. As a result of these measures, the
Board has successfully completed £1.3 million of annualised cost savings which
will be realised in 2008 through headcount reduction across the operations and
at HQ. The Board estimate that restructuring costs relating to the realisation
of these savings will be £0.6 million and the aborted transaction costs will be
£0.5 million. Both these costs will be treated as non-trading items in 2007.
The Board will review the optimal structure of the Group and continue to pursue
opportunities to enhance shareholder value.
Contacts:
Huveaux PLC 020 7245 0270
John van Kuffeler, Chairman
Kevin Hand, Deputy Chairman
Gerry Murray, Chief Executive Officer
Dresdner Kleinwort 020 7623 8000
Charlie Batten
Dresdner Kleinwort Limited:
Dresdner Kleinwort Limited, which is authorised and regulated by the Financial
Services Authority, is acting for Huveaux PLC and for no-one else in connection
with the contents of this announcement and will not be responsible to anyone
other than Huveaux PLC for providing the protections afforded to customers of
Dresdner Kleinwort Limited, or for affording advice in relation to the contents
of this document or any matters referred to herein.
END
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.